Bristol-Myers Gets U.S. Approval for Wider Erbitux Use

Bristol-Myers Squibb Co. and Eli Lilly & Co. won U.S. regulatory approval to expand the use of Erbitux as an initial treatment against colorectal cancer that has spread for patients who are first given a genetic screening.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.